title: [Treatment results of children with neuroblastoma: report of Polish Pediatric Solid Tumor Group].
abstract: Approximately 60 children aged 0-18 years are diagnosed of NBL each year in Poland. About 60% of all patients suffering from NBL have a chance for durable cure. Unfortunately the prognosis for patients within the high-risk group accounting for more than 50% of all NBL patients remains poor despite the introduction of more intensive chemotherapy regimens with radical surgery procedures and megachemotherapy with subsequent stem cell transplantation. Only one third of patients in this group can be cured. To improve the treatment results of the high-risk patient group and to decrease the rate of therapy related side effects current European treatment protocols have been introduced systematically in Poland. In February 2009 information about 389 patients (age 0.1-16.5 years) diagnosed between 2001 and 2008 were obtained. Results of therapy of 319 patients who started treatment from 2001 to 2007 were analyzed. Between 104 infants and 215 children over 1 year of age, stage 4 of disease was found in 25% and 54.5%, respectively. In this period additionally to European treatment protocols, two another protocols were used. Satisfactory treatment results were obtained in 104 infants (5-year event free survival /EFS/=82.6%), irrespective of the type of treatment protocol. Over 5-year EFS for children over 1 year of age in 1, 2 and 3 stage of disease was: 100%, 86.3% and 64.5%, respectively. On the contrary, 107 patients with 4 stage of disease achieved the 5-year EFS of 27% only. Treatment results obtained in patients treated according to the European HR-NBL-1/ESIOP protocol were better than for patients treated according to other treatment protocols (5-year EFS: 31.1% and 16.4%, respectively), but difference between these groups was not significant. Between 2001 and 2007 data reporting increased to 81% from 19% noted earlier. Unfortunately, results of treatment for children over 1 year of age remain still unsatisfactory. That is why there is a need of improvement of modern, unified treatment realization as well as better data reporting. For realization of these aims adequate financial support is essential.
authors.affiliation: Klinika Onkologii i Hematologii Dzieciecej, P-A IP, UJ-CM w Krakowie. walentyna@balwierz.com
authors.forename: Walentyna
authors.initials: W
authors.lastname: Balwierz
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Wieczorek
authors.forename: Tomasz
authors.initials: T
authors.lastname: Klekawka
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Garus
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Bolek-Marzec
authors.forename: Danuta
authors.initials: D
authors.lastname: Perek
authors.forename: Ewa
authors.initials: E
authors.lastname: Swieszkowska
authors.forename: Wojciech
authors.initials: W
authors.lastname: Młynarski
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Stolarska
authors.forename: Jerzy R
authors.initials: JR
authors.lastname: Kowalczyk
authors.forename: Joanna
authors.initials: J
authors.lastname: Nurzyńska-Flak
authors.forename: Anna
authors.initials: A
authors.lastname: Balcerska
authors.forename: Ewa
authors.initials: E
authors.lastname: Bień
authors.forename: Jacek
authors.initials: J
authors.lastname: Wachowiak
authors.forename: Danuta
authors.initials: D
authors.lastname: Januszkiewicz-Lewandowska
authors.forename: Wojciech
authors.initials: W
authors.lastname: Woźniak
authors.forename: Anna
authors.initials: A
authors.lastname: Raciborska
authors.forename: Alicja
authors.initials: A
authors.lastname: Chybicka
authors.forename: Marek
authors.initials: M
authors.lastname: Ussowicz
authors.forename: Maryna
authors.initials: M
authors.lastname: Krawczuk-Rybak
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Muszyńska-Rosłan
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
authors.forename: Sylwia
authors.initials: S
authors.lastname: Kołtan
authors.forename: Grazyna
authors.initials: G
authors.lastname: Sobol
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Mizia-Malarz
authors.forename: Tomasz
authors.initials: T
authors.lastname: Urasiński
authors.forename: Jarosław
authors.initials: J
authors.lastname: Peregut-Pogorzelski
authors.forename: Danuta
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: Halina
authors.initials: H
authors.lastname: Bubała
authors.forename: Maria
authors.initials: M
authors.lastname: Wieczorek
authors.forename: Michał
authors.initials: M
authors.lastname: Matysiak
authors.forename: Barbara
authors.initials: B
authors.lastname: Sopyło
authors.forename: Wojciech
authors.initials: W
authors.lastname: Madziara
mesh_terms: D000293:Adolescent; D017677:Age Distribution; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D011044:Poland / Q000453:epidemiology; D011379:Prognosis; D016896:Treatment Outcome